Two dosage schedules of co-trimoxazole, the standard antibacterial and a 2-day high-dose schedule, were compared with a standard course of chloroquine in the treatment of uncomplicated Plasmodium falciparum malaria. Parasites were cleared from the blood at similar rates, but pyrexia responded more slowly following the standard cotrimoxazole dose. No recrudescences were detected in those observed for up to 60 days after treatment.

Download full-text PDF

Source

Publication Analysis

Top Keywords

plasmodium falciparum
8
falciparum malaria
8
evaluation co-trimoxazole
4
co-trimoxazole treatment
4
treatment plasmodium
4
malaria dosage
4
dosage schedules
4
schedules co-trimoxazole
4
co-trimoxazole standard
4
standard antibacterial
4

Similar Publications

The human malaria parasite Plasmodium falciparum evolved from a parasite that infects gorillas, termed Plasmodium praefalciparum. The sialic acids on glycans on the surface of erythrocytes differ between humans and other apes. It has recently been shown that the P.

View Article and Find Full Text PDF

Guillain-Barré syndrome following falciparum malaria infection: a case report.

BMC Neurol

January 2025

Department of Radiology, School of Medicine, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Teferi, Ethiopia.

Background: Malaria is an infectious disease caused by Plasmodium parasites, transmitted to humans by infected female Anopheles mosquitoes. Five Plasmodium species infect humans: P. vivax, P.

View Article and Find Full Text PDF

Genetically attenuated parasites show promise as a next-generation malaria vaccine.

Trends Parasitol

January 2025

Department of Molecular Parasitology, Institute of Biology, Humboldt Universität zu Berlin, 10115 Berlin, Germany. Electronic address:

Metabolically active, genetically attenuated Plasmodium falciparum parasite lines are promising second-generation malaria vaccine candidates. Lamers et al. and Roozen et al.

View Article and Find Full Text PDF

Clarification of factors associated with post-artesunate delayed hemolysis (PADH): analysis of 327 patients with severe imported Plasmodium falciparum malaria in France.

Travel Med Infect Dis

January 2025

Centre National de Référence du Paludisme, Paris, France; Centre de Recherche en Epidémiologie et Santé des Populations (CESP), INSERM U1018, Paris, France; Université Paris-Saclay, Service des Maladies infectieuses et tropicales, APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Société Française de Médecine des Voyages.

Background: Post-Artesunate delayed hemolysis (PADH) occurs in approximately 15% of treated patients 2 to 3 weeks after artesunate administration. Identifying risk markers for PADH would help predict which patients are at higher risk.

Methods: In this prospective national cohort study conducted in a non-malaria endemic area from 2011 to 2016, a Cox proportional hazards model was used to assess the association between clinical and biological data available at Day 0 and the occurrence of PADH within 30 days of artesunate administration.

View Article and Find Full Text PDF

Malaria remains a global health concern, with 249 million cases and 608,000 deaths being reported by the WHO in 2022. Traditional diagnostic methods often struggle with inconsistent stain quality, lighting variations, and limited resources in endemic regions, making manual detection time-intensive and error-prone. This study introduces an automated system for analyzing Romanowsky-stained thick blood smears, focusing on image quality evaluation, leukocyte detection, and malaria parasite classification.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!